Skip to main content

Bioprognos OncoCUP Dx

Spanish biotech firm Bioprognosis introduced a new version of its OncoCUP Dx, a noninvasive test for identifying cancers of unknown primary diagnosis. The test was developed and tested "in collaboration with few quick diagnosis units," an outpatient model for diagnostic workups that are used in Europe. QDUs are an alternative to hospitallizations and are designed to reduce delays in diagnosing potentially severe diseases. Among the cancers that OncoCUP Dx can identify are bladder cancer, breast cancer, colorectal cancer, liver cancer, and non-small cell lung cancer, Bioprognosis said.